2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA VALIDATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH 3 AVAILABLE TKIS OUTSIDE CLINICAL TRIALS

被引：0
|
作者：
Breccia, M. [1 ]
Pregno, P. [2 ]
Annunziata, M. [3 ]
Orlandi, E. [4 ]
Gozzini, A. [5 ]
Iurlo, A. [6 ]
Bocchia, M. [7 ]
Franceschini, L. [8 ]
Montefusco, E. [9 ]
Crugnola, M. [10 ]
La Nasa, G. [11 ]
Scortechini, A. R. [12 ]
Sgherza, N. [13 ]
Sica, S. [14 ]
Alimena, G. [1 ]
Saglio, G. [15 ]
Specchia, G. [16 ]
机构：
[1] Univ Roma La Sapienza, Hematol, Dept Cellular Biotechnol & Hematol, Rome, Italy
[2] Citta Salute & Sci Torino AOU, Hematol, Turin, Italy
[3] Cardarelli Hosp, Hematol, Naples, Italy
[4] Fdn IRCSS Policlin San Matteo, Hematol, Pavia, Italy
[5] Careggi Hosp AOU, Hematol, Florence, Italy
[6] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Hematol, Milan, Italy
[7] Univ Siena, Hematol, Siena, Italy
[8] Univ Roma Tor Vergata, Rome, Italy
[9] S Andrea Hosp, Hematol, Rome, Italy
[10] Parma AOU, Hematol, Parma, Italy
[11] Univ Cagliari, Hematol, Dept Med Sci, Cagliari, Italy
[12] Osped Riuniti Ancona, Hematol, Ancona, Italy
[13] IRCSS Ist Tumori Giovanni Paolo II, Hematol, Bari, Italy
[14] Univ Cattolica, Hematol, Rome, Italy
[15] Univ Turin, Hematol, Turin, Italy
[16] Policlin Consorziale Bari AOU, Hematol, Bari, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1827
引用
收藏
页码：738 / 739
页数：2
相关论文
共 50 条
  • [1] ESTIMATED GLOMERULAR FILTRATION RATE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH AVAILABLE TKIS AND CORRELATION WITH CARDIOVASCULAR EVENTS
    Breccia, M.
    Molica, M.
    Canichella, M.
    Fegatelli, D. Alunni
    Ranieri, S. Chiatamone
    Massaro, F.
    Colafigli, G.
    Latagliata, R.
    Alimena, G.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 82 - 82
  • [2] Effects of Intermittent Fasting on Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia: An Outcome of European LeukemiaNet Project
    Yassin, Mohamed A.
    Ghasoub, Rola S.
    Aldapt, Mahmood B.
    Abdulla, Mohammad A.
    Chandra, Prem
    Shwaylia, Hawraa M.
    Nashwan, Abdulqadir J.
    Kassem, Nancy A.
    Akiki, Susanna J.
    CANCER CONTROL, 2021, 28
  • [3] Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet
    Guilhot, Joelle
    Baccarani, Michele
    Clark, Richard E.
    Cervantes, Francisco
    Guilhot, Francois
    Hochhaus, Andreas
    Kulikov, Sergei
    Mayer, Jiri
    Petzer, Andreas L.
    Rosti, Gianantonio
    Rousselot, Philippe
    Saglio, Giuseppe
    Saussele, Susanne
    Simonsson, Bengt
    Steegmann, Juan-Luis
    Zaritskey, Andrey
    Hehlmann, Ruediger
    BLOOD, 2012, 119 (25) : 5963 - 5971
  • [4] A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria
    Murai, Kazunori
    Akagi, Tomoaki
    Shimosegawa, Kenji
    Sugawara, Tomohiro
    Ishizawa, Kenichi
    Ito, Shigeki
    Murai, Keiko
    Motegi, Mutsuhito
    Yokoyama, Hisayuki
    Noji, Hideyoshi
    Tajima, Katsushi
    Kimura, Jun
    Chou, Takaaki
    Ogawa, Kazuei
    Harigae, Hideo
    Kubo, Kohmei
    Oba, Koji
    Sakamoto, Junichi
    Ishida, Yoji
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (06) : 558 - 565
  • [5] Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
    Luciano, Luigia
    Latagliata, Roberto
    Gugliotta, Gabriele
    Annunziata, Mario
    Tiribelli, Mario
    Martino, Bruno
    Sica, Antonello
    Esposito, Maria Rosaria
    Bocchia, Monica
    Galimberti, Sara
    Sora, Federica
    Albano, Francesco
    Palmieri, Raffaele
    Pregno, Patrizia
    Dragani, Matteo
    Iovine, Maria
    Sica, Simona
    Iurlo, Alessandra
    Castagnetti, Fausto
    Rosti, Gianantonio
    Breccia, Massimo
    ANNALS OF HEMATOLOGY, 2023, 102 (06) : 1375 - 1382
  • [6] Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
    Luigia Luciano
    Roberto Latagliata
    Gabriele Gugliotta
    Mario Annunziata
    Mario Tiribelli
    Bruno Martino
    Antonello Sica
    Maria Rosaria Esposito
    Monica Bocchia
    Sara Galimberti
    Federica Sorà
    Francesco Albano
    Raffaele Palmieri
    Patrizia Pregno
    Matteo Dragani
    Maria Iovine
    Simona Sica
    Alessandra Iurlo
    Fausto Castagnetti
    Gianantonio Rosti
    Massimo Breccia
    Annals of Hematology, 2023, 102 : 1375 - 1382
  • [7] Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide
    Carlos Hernandez-Boluda, Juan
    Pereira, Arturo
    Cervantes, Francisco
    Gomez, Montse
    Arellano-Rodrigo, Eduardo
    Alvarez-Larran, Alberto
    Ferrer-Marin, Francisca
    Kerguelen, Ana
    Antonio Marquez, Jose
    Luisa Antelo, Maria
    Besses, Carles
    ANNALS OF HEMATOLOGY, 2013, 92 (06) : 771 - 775
  • [8] Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide
    Juan Carlos Hernández-Boluda
    Arturo Pereira
    Francisco Cervantes
    Montse Gómez
    Eduardo Arellano-Rodrigo
    Alberto Alvarez-Larrán
    Francisca Ferrer-Marín
    Ana Kerguelen
    José Antonio Márquez
    María Luisa Antelo
    Carles Besses
    Annals of Hematology, 2013, 92 : 771 - 775
  • [9] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH IMATINIB MESYLATE
    Castagnetti, F.
    Gugliotta, G.
    Breccia, M.
    Albano, F.
    Abruzzese, E.
    Levato, L.
    Cavazzini, F.
    Lurlo, A.
    Stagno, F.
    Ferrero, D.
    Porretto, F.
    Martino, B.
    Rupoli, S.
    Intermesoli, T.
    Fava, C.
    Pierri, I.
    Palandri, F.
    Venturi, C.
    Soverini, S.
    Luatti, S.
    Alimena, G.
    Pane, F.
    Martinelli, G.
    Saglio, G.
    Cavo, M.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2013, 98 : 59 - 59
  • [10] Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials
    Suh, Koung Jin
    Lee, Ji Yun
    Shin, Dong-Yeop
    Koh, Youngil
    Bang, Soo-Mee
    Yoon, Sung-Soo
    Park, Seonyang
    Kim, Inho
    Lee, Jeong-Ok
    BLOOD, 2016, 128 (22)
12345